Our team.

About Cristina Escoda

Dr Cristina Escoda has been a founder, advisor and investor in early-stage deep science ventures for over 10 years. Alongside Tachyon, she continues to be actively involved in several startups, and most recently co-founded ORCA Computing Ltd, a spin-out from Oxford University developing the first quantum computer in optical fiber.

Cristina started her career as a financial derivatives structurer for HSBC LatAm in NYC, and later joined the rotational associate program at D.E. Shaw & Co. - the multinational investment management firm founded in 1988 by David E. Shaw in NYC. There she worked on a variety of initiatives, including new business ideation, emerging markets analysis, quant algorithm development and non-traditional asset class products.

Cristina has worked in portfolio management and in product development in the fin-tech, digital health and blockchain sectors. She holds a PhD in Theoretical Physics and a masters in Mathematics from Cambridge University (UK) and an MBA from NYU Stern.

About Ernest Turro

Dr Ernest Turro is a biostatistician with 15 years of experience in genetics, molecular diagnostics and genomics research. Ernest has authored more than 60 peer-reviewed articles, with published work as a senior author in Nature, Science, Blood and the American Journal of Human Genetics, among others.

Ernest is an Associate Professor at the Icahn School of Medicine at Mount Sinai and a Visiting Researcher at the University of Cambridge, where he worked between 2011 and 2020. His research focuses primarily on the development and application of statistical methods for interpreting genomic and phenotypic data, with a focus on understanding the causes of rare diseases.

Ernest was the lead statistician of the National Institute for Health Research-funded precursor to the UK's 100,000 Genomes Project. During that time, he also supervised the computational aspects of a high-throughput platform for diagnosing bleeding, thrombotic and platelet disorders. Previously, he developed several influential methods for analysing RNA sequencing data, and he has collaborated with various research groups on their application in diverse fields of biology.

He holds a PhD in Biostatistics and an MSc in Computing Science, both from Imperial College London, and a BSc in Economics & Politics from the University of Bristol.

About Josep Turro

Josep Turro is a Partner and Investment Committee member at Tachyon. He is also co-founder and President of the Advisory Committee of Barcino Property Socimi, a REIT focused on Spanish real-estate that IPO’d in 2017.

Previously he was CEO of IAD Spain and UK Special Advisor to the IAD Group, a proptech business that became a unicorn in 2021.

Josep brings to Tachyon more than 20 years of experience in private equity, M&A, fund management and business development. Josep has spent most of his career in London, and has worked at Deutsche Bank, IK Partners, GMT Comm. Partners, Ironshield Capital, and Societe Generale.

Josep holds a MSc Econ/Phil from the London School of Economics, and a BA in Mathematics & Philosophy from Oxford University. Josep is a CFA charterholder.

About Neil Deramchi

Neil is a PE and VC strategist with experience across biotech, wellness, blockchain and e-commerce. Alongside Tachyon, she runs her own tech & brand strategy consultancy. She is based in Los Angeles and holds a BS in Biochemistry from UCLA as well as an MS in Translational Biotechnology from USC's Keck School of Medicine.

Thomas Dadashi has been investing in venture secondaries for over 15 years. He leads Tachyon's secondaries strategy through a partnership between Tachyon and eNTIER Capital, the firm he co-founded in 2019 to provide liquidity and capital solutions to venture-backed companies and investors across Europe.

Thomas started his career in PwC's Transaction Services practice in Paris, working on financial due diligence across M&A and LBO deals. He later joined Akina, a private equity firm in Zurich, sourcing and executing secondary and direct growth and buyout investments across Europe. He joined TempoCap in 2016 as an Investment Partner focused on growth and venture capital secondaries. Thomas is also an active business angel.

Thomas has invested in companies like Revolut, Darktrace, Depop, Onfido and Voodoo. He holds a Masters in Finance from EDHEC Business School and studied at the European Business School in Germany.

Jaime is a medtech, biotech, and diagnostics executive with global experience growing private startups and larger public companies, focused on business development and corporate strategy. He has advised numerous VC and PE investors across life sciences on both sides of the Atlantic.

With more than 20 years of professional experience in DeepTech and industry-academia partnerships (Industrial and Bioengineering R&D). He holds two areas of expertise, both Life Sciences and Sustainability. At Inveniam he develops the Venture Building activity through specialized consulting and private & public Fundraising through his vast experience in Tech Transfer in Medtech, Biotech, Digital Health, Renewable Energy, Smart Grids, Energy Storage, etc.Albert manages INNCOM, a Corporate Venture program for COMSA Corporation leading intrapreneurship projects. He also serves as a member of the Industrial Engineering Association of Catalonia board and an Associate Professor in the Faculty of Medicine of the UAB.

Elena is an international expert in Technology Transfer. Having completed hundreds of licensing and research deals in the pharmaceutical, high-tech and chemical industries, Elena brings years of experience with tech commercialization in international markets. Prior to co-founding Inveniam, Elena was VP of Research Collaborations at a worldwide renowned Israeli University, where she led the commercialization of promising technologies to international corporations and leading venture capital firms.

Jesús is a biologist turned science manager turned social entrepreneur. He founded, and currently leads, Àvida Biotech. Feeling the obligation to communicate science to broader audiences, part of this work is to help researchers and clinicians with their efforts to bring the results of their work to society.